Unveiling the Truth: Ulcerative Proctitis and Rectal Cancer Risk
Are people with ulcerative proctitis, a milder form of ulcerative colitis, at a higher risk of developing rectal cancer? A new Swedish registry study from Karolinska Institutet has provided some much-needed clarity on this topic. The findings, published in Gastroenterology, reveal that individuals with ulcerative proctitis are not at an increased risk of rectal cancer compared to the general population.
Ulcerative colitis has long been associated with a higher risk of colon or rectal cancer, but the extent of this risk varies depending on the severity and location of the inflammation. For ulcerative proctitis, where the inflammation is confined to the rectum, the link with rectal cancer has been unclear. This study aimed to shed light on this specific question.
The researchers identified nearly 16,000 individuals in Sweden diagnosed with isolated ulcerative proctitis between 1997 and 2023. These participants were compared with over 158,000 people from the general population who did not have inflammatory bowel disease. By linking several national health registries, the researchers could follow the participants for a median of over ten years.
The results were reassuring. The incidence of rectal cancer and precancerous lesions, known as high-grade dysplasia, was very low in both groups. After ten years of follow-up, approximately 0.2 percent of both the patient group and the comparison group had developed rectal cancer. The study also found no increased risk of rectal cancer in patients who later developed more widespread colitis.
"Our findings are a ray of hope for individuals with ulcerative proctitis. Despite the long-term inflammation in the rectum, we found no increased risk of cancer compared to the general population," says Åsa Hallqvist Everhov, senior physician in surgery and associate professor at the Department of Clinical Epidemiology, Institute of Medicine Solna, Karolinska Institutet, and first author of the study.
"This supports a more individualized approach to cancer surveillance in inflammatory bowel disease, where the extent of the disease plays a crucial role," adds Ola Olén, senior physician in pediatric gastroenterology and adjunct professor at the Department of Clinical Epidemiology, Institute of Medicine, Solna, Karolinska Institutet.
The study was based on prospective data from various sources, including the national IBD registry SWIBREG, the Cancer Registry, and the Patient Registry. Funding came from several organizations, including the Swedish Research Council, the Cancer Foundation, the Bengt Ihre Foundation, and ALF funds from Region Stockholm. Several researchers reported collaborations or support from pharmaceutical companies, while others had no conflicts of interest.
Publication:
"Incidence of Rectal Cancer in Patients with Isolated Ulcerative Proctitis - A Population-Based Cohort Study," Åsa H Everhov, Jonas F Ludvigsson, Kari Kristjansson, Pär Myrelid, Henrik Toft Sørensen, Ola Olén, Gastroenterology, online 3 February 2026.
But here's where it gets controversial... The study's findings may prompt some to question the need for extensive cancer surveillance in ulcerative proctitis patients. However, it's essential to remember that this study provides a general overview, and individual cases may vary. As always, further research is needed to fully understand the long-term implications of ulcerative proctitis and its management.
What do you think? Do you agree with the study's findings, or do you have a different perspective? Share your thoughts in the comments below!
